Aktuellt
SENASTE
Redeye provides an update on ChromoGenics following the company's Q1 2023 results. ChromoGenics continues to add strategic partners and the focus continues to be on sales activities and cost control. Sales came in lower than expected in the quarter and we expect OPEX to continue to be on the high side for longer and therefore lowers operational margings somewhat. Due to this, we adjust the valuation range to SEK0.07(0.04)–0.49 (0.043) with a base case of SEK0.10 (0.11).
LÄS MER
